Literature DB >> 16778719

Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates.

Joyce Pullen1, Lindsay de Rozario, Leo M L Stolk, Pieter L J Degraeuwe, Frank H van Tiel, Luc J I Zimmermann.   

Abstract

In total 235 flucloxacillin total (free+protein bound) plasma concentrations were determined in 55 neonates (gestational age 26 to 42 weeks, postnatal age 0 to 44 days) with reversed-phase HPLC in surplus plasma samples from routine gentamicin assays. Population pharmacokinetic parameters were calculated according to an one compartment open model with iterative two-stage Bayesian fitting (MWPHARM 3.50, Mediware, The Netherlands). Mean clearance corrected for weight was 0.18+/-0.10 L kgh and volume of distribution corrected for weight was 0.54+/-0.17 L/kg. Pearson correlations between the individual pharmacokinetic parameters and covariates, like gestational age, plasma creatinine, and gentamicin clearance, were low and therefore not relevant for use in clinical practice. Total plasma concentrations above 200 mg/L were considered toxic and T>MIC (time above minimum inhibitory free plasma concentration) of more than 40% was considered effective. Protein binding was assumed to be 86.3% in all neonates, based on literature. The current dosage regimen, 25 or 50 mg/kg every 8 or 12 hours, did not result in effective plasma concentrations for the treatment of Staphylococcus aureus in 17 (31%) of the 55 neonates. Therefore, the authors suggest an initial dose of 25 mg/kg/4 h for all neonates, irrespective of their age, based on the breakpoint MIC value of flucloxacillin for Staphylococcus aureus (2.0 mg/L). After isolation of the causative agent of infection, flucloxacillin administration ought to be reconsidered based on the expected susceptibility pattern of the isolate. When oxacillin sensitive coagulase negative staphylococci are isolated, the initial dose should be reduced to 10 mg/kg/6 h, based on the breakpoint MIC value of 0.25 mg/L. Simulation with these new dosage regimens indicated that satisfactory plasma concentrations were reached in 52 of the 55 neonates. However, the regimens need prospective verification. Moreover, the exact role of neonatal protein binding needs to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778719     DOI: 10.1097/01.ftd.0000211831.96102.91

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

1.  Effective CSF concentrations achieved with continuous-infusion flucloxacillin in a child.

Authors:  Alison Boast; Jeremy Carr; Nigel Curtis; Andrew J Daley; Amanda Gwee
Journal:  Eur J Clin Pharmacol       Date:  2015-08-26       Impact factor: 2.953

Review 2.  Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics.

Authors:  Christopher M Rubino; John S Bradley
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 3.  Clinical pharmacokinetics of penicillins in the neonate: a review of the literature.

Authors:  G M Pacifici; J Labatia; H Mulla; I Choonara
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

Review 4.  Pharmacokinetic studies in infants using minimal-risk study designs.

Authors:  Julie Autmizguine; Daniel K Benjamin; P Brian Smith; Mario Sampson; Philippe Ovetchkine; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Curr Clin Pharmacol       Date:  2014

5.  Design and prospective validation of a dosing instrument for continuous infusion of vancomycin: a within-population approach.

Authors:  Erik M van Maarseveen; Annemien Bouma; Daniel J Touw; Cees Neef; Arthur R H van Zanten
Journal:  Eur J Clin Pharmacol       Date:  2014-08-30       Impact factor: 2.953

Review 6.  Population pharmacokinetic analysis during the first 2 years of life: an overview.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

Review 7.  Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.

Authors:  Charlotte I S Barker; Eva Germovsek; Rollo L Hoare; Jodi M Lestner; Joanna Lewis; Joseph F Standing
Journal:  Adv Drug Deliv Rev       Date:  2014-01-17       Impact factor: 15.470

Review 8.  Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review.

Authors:  Gian Maria Pacifici
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.